The firm is exploring a path forward for its gene-editing drug for chronic granulomatous disease, after saying last year it ...

The companies will use Ascidian Therapeutics' RNA exon-editing tech to develop treatments for undisclosed monogenic kidney diseases.

The firm said it will use the funds to study WAY-103 in gastric and pancreatic tumors and advance its AI and spatial biology discovery platform.

At ASCO, researchers shared that in the persevERA trial, giredestrant didn't improve outcomes for first-line advanced breast ...

Data presented at ASCO showed that patients who achieved at least 80 percent KRAS G12C ctDNA clearance experienced prolonged survival.

Analysis of samples from the NATALEE trial, presented at ASCO, revealed some response-linked gene-expression patterns, but ...

Eli Lilly announced a deal to buy the Boston biotech Kelonia for up to $7 billion last month after early results made a ...

The firm will advance rugonersen, a drug previously developed and then dropped by Roche, into a pivotal Phase III trial.

CHICAGO – Eli Lilly's Retevmo (selpercatinib) could be a new option for patients with non-small cell lung cancer to prevent recurrence after surgery, according to data that the company already ...

In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.

Over the weekend, the firm reported final data readouts for two Galleri studies and held an analyst call to highlight positive takeaways.